After three years of work, researchers at Case Western Reserve University have identified why certain brain cells die in Parkinson's disease—and found a way to stop it in the lab.
The culprit is a toxic interaction between two proteins. Alpha-synuclein, a protein that accumulates in Parkinson's brains, latches onto an enzyme called ClpP that normally keeps cells running smoothly. When this happens, the cell's mitochondria—the powerhouses that supply energy—start to fail. Without energy, neurons that control movement begin to die.
"We've uncovered a harmful interaction between proteins that damages the brain's cellular powerhouses," said Xin Qi, the study's senior author and a brain sciences professor at Case Western. "More importantly, we've developed a targeted approach that can block this interaction and restore healthy brain cell function."
We're a new kind of news feed.
Regular news is designed to drain you. We're a non-profit built to restore you. Every story we publish is scored for impact, progress, and hope.
Start Your News DetoxThe team's solution is a compound called CS2, which works like a decoy. It binds to alpha-synuclein before the protein can attack ClpP, essentially stepping in to protect the cell's energy system. In experiments using human brain tissue, neurons grown from Parkinson's patients, and mouse models, CS2 reduced brain inflammation and improved both movement and cognitive performance.
This matters because most Parkinson's treatments today manage symptoms—tremors, stiffness, slowness—rather than addressing what's actually happening inside the cell. CS2 targets the root cause. "Instead of just treating the symptoms, we're targeting one of the root causes of the disease itself," said Di Hu, a research scientist on the team.
The work, published in Molecular Neurodegeneration in 2025, is still in early stages. Researchers plan to spend the next five years refining the therapy, running safety and effectiveness studies, and identifying biomarkers that could predict disease progression. The goal is to move toward human trials—and eventually, a treatment that transforms Parkinson's from a progressive condition into something manageable or even reversible.
For the roughly one million people living with Parkinson's in the U.S. alone, the pathway is becoming clearer. The science is moving from "why this happens" to "how we can stop it."
